Document is current
Any future updates will be listed below
-
Authors
Terashima, Takeshi
Nio, Kouki
Koshikawa, Naohiko
Ueno, Makoto
Toyama, Tadashi
Miyazawa, Masaki
Hayashi, Tomoyuki
Seki, Akihiro
Nakagawa, Hidetoshi
Iida, Noriho
Yamada, Shinya
Takatori, Hajime
Shimakami, Tetsuro
Yoshimura, Toru
Yoshida, Eisaku
Nakagawa, Masatoshi
Seiki, Motoharu
Yamashita, Taro
-
Funding
Funding for this research was provided by:
JSPS KAKENHI Grant (JP18ck0106425, JP19ck0106425, JP20ck0106425, JP21ck0106662h0001, JP21ck0106662h0002, and JP21ck0106662h0003)
- License Information
-
More Information
Article History
Received: 22 August 2024
Revised: 21 November 2024
Accepted: 18 December 2024
First Online: 14 January 2025
Competing interests
: MU received honoraria from Taiho Pharmaceutical Co., Ltd., AstraZeneca, K.K, Yakult Honsha Co., Ltd., MSD K.K, Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Incyte Biosciences Japan GK, Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, J-pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Novartis Pharma K.K. and research Funding from Taiho Pharmaceutical Co., Ltd., AstraZeneca, K.K, MSD K.K, Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Incyte Biosciences Japan GK, Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, Eisai Co., Ltd., Novartis Pharma K.K, Astellas Pharma Inc., J-pharma Co., Ltd., DFP (Delta Fly Pharma), Inc., Novocure GmbH, and Chiome Bioscience Inc.
: The Institutional Review Boards of Kanazawa University Hospital and of Kanagawa Cancer Center approved the study protocol, and the study was conducted in accordance with the Declaration of Helsinki.
: Informed consent from the patients obtained for all medical procedures and participation to this study.
: Informed consent from the patients obtained for publication of this report.
